vs
Side-by-side financial comparison of FVCBankcorp, Inc. (FVCB) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
FVCBankcorp, Inc. is the larger business by last-quarter revenue ($16.9M vs $9.3M, roughly 1.8× STRATA Skin Sciences, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs -3.0%). FVCBankcorp, Inc. produced more free cash flow last quarter ($23.8M vs $-551.0K). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs 17.3%).
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
FVCB vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.9M | $9.3M |
| Net Profit | — | $58.0K |
| Gross Margin | — | 61.8% |
| Operating Margin | 43.7% | 5.3% |
| Net Margin | — | 0.6% |
| Revenue YoY | 4377.5% | -3.0% |
| Net Profit YoY | — | 101.3% |
| EPS (diluted) | $0.31 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.9M | $9.3M | ||
| Q3 25 | $416.0K | $6.9M | ||
| Q2 25 | $15.8M | $7.7M | ||
| Q1 25 | $382.0K | $6.8M | ||
| Q4 24 | $378.0K | $9.6M | ||
| Q3 24 | $412.0K | $8.8M | ||
| Q2 24 | $415.0K | $8.4M | ||
| Q1 24 | $359.0K | $6.8M |
| Q4 25 | — | $58.0K | ||
| Q3 25 | $5.6M | $-1.6M | ||
| Q2 25 | $5.7M | $-2.6M | ||
| Q1 25 | $5.2M | $-2.1M | ||
| Q4 24 | — | $-4.6M | ||
| Q3 24 | $4.7M | $-2.1M | ||
| Q2 24 | $4.2M | $-91.0K | ||
| Q1 24 | $1.3M | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | 43.7% | 5.3% | ||
| Q3 25 | — | -16.9% | ||
| Q2 25 | 45.9% | -30.1% | ||
| Q1 25 | — | -25.0% | ||
| Q4 24 | — | -44.7% | ||
| Q3 24 | — | -18.2% | ||
| Q2 24 | — | -5.7% | ||
| Q1 24 | — | -42.7% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | 1341.1% | -23.4% | ||
| Q2 25 | 36.0% | -33.6% | ||
| Q1 25 | 1352.1% | -31.2% | ||
| Q4 24 | — | -47.6% | ||
| Q3 24 | 1133.3% | -23.6% | ||
| Q2 24 | 1001.2% | -1.1% | ||
| Q1 24 | 373.3% | -49.8% |
| Q4 25 | $0.31 | $0.14 | ||
| Q3 25 | $0.31 | $-0.36 | ||
| Q2 25 | $0.31 | $-0.62 | ||
| Q1 25 | $0.28 | $-0.51 | ||
| Q4 24 | $0.27 | $-2.01 | ||
| Q3 24 | $0.25 | $-0.51 | ||
| Q2 24 | $0.23 | $-0.03 | ||
| Q1 24 | $0.07 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $253.6M | $2.9M |
| Total Assets | $2.3B | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.9M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $6.0M | ||
| Q1 25 | — | $6.5M | ||
| Q4 24 | — | $7.3M | ||
| Q3 24 | — | $7.1M | ||
| Q2 24 | — | $5.5M | ||
| Q1 24 | — | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $253.6M | $2.9M | ||
| Q3 25 | $249.8M | $1.3M | ||
| Q2 25 | $243.2M | $532.0K | ||
| Q1 25 | $242.3M | $3.0M | ||
| Q4 24 | $235.4M | $5.0M | ||
| Q3 24 | $230.8M | $9.4M | ||
| Q2 24 | $226.5M | $9.5M | ||
| Q1 24 | $220.7M | $9.4M |
| Q4 25 | $2.3B | $30.5M | ||
| Q3 25 | $2.3B | $30.7M | ||
| Q2 25 | $2.2B | $29.5M | ||
| Q1 25 | $2.2B | $33.0M | ||
| Q4 24 | $2.2B | $34.9M | ||
| Q3 24 | $2.3B | $39.4M | ||
| Q2 24 | $2.3B | $38.8M | ||
| Q1 24 | $2.2B | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $23.9M | $-239.0K |
| Free Cash FlowOCF − Capex | $23.8M | $-551.0K |
| FCF MarginFCF / Revenue | 140.7% | -5.9% |
| Capex IntensityCapex / Revenue | 0.3% | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $40.0M | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.9M | $-239.0K | ||
| Q3 25 | $7.6M | $-64.0K | ||
| Q2 25 | $3.3M | $-1.9M | ||
| Q1 25 | $5.4M | $-550.0K | ||
| Q4 24 | $18.2M | $703.0K | ||
| Q3 24 | $4.7M | $-302.0K | ||
| Q2 24 | $1.6M | $591.0K | ||
| Q1 24 | $7.2M | $-804.0K |
| Q4 25 | $23.8M | $-551.0K | ||
| Q3 25 | $7.6M | $-1.1M | ||
| Q2 25 | $3.3M | $-2.0M | ||
| Q1 25 | $5.4M | $-749.0K | ||
| Q4 24 | $18.1M | $199.0K | ||
| Q3 24 | $4.6M | $-364.0K | ||
| Q2 24 | $1.5M | $246.0K | ||
| Q1 24 | $7.1M | $-1.5M |
| Q4 25 | 140.7% | -5.9% | ||
| Q3 25 | 1818.0% | -15.6% | ||
| Q2 25 | 20.8% | -26.1% | ||
| Q1 25 | 1413.6% | -11.0% | ||
| Q4 24 | 4786.0% | 2.1% | ||
| Q3 24 | 1121.8% | -4.1% | ||
| Q2 24 | 361.2% | 2.9% | ||
| Q1 24 | 1988.3% | -22.6% |
| Q4 25 | 0.3% | 3.4% | ||
| Q3 25 | 0.2% | 14.7% | ||
| Q2 25 | 0.1% | 0.8% | ||
| Q1 25 | 4.2% | 2.9% | ||
| Q4 24 | 37.3% | 5.3% | ||
| Q3 24 | 14.1% | 0.7% | ||
| Q2 24 | 12.8% | 4.1% | ||
| Q1 24 | 3.9% | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 5.34× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVCB
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
